PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Cyproheptadine→

Cyproheptadine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
129-03-3
Molecular formula
C21H21N
Molecular weight
287.3981 g/mol
Drug class
First-generation antihistamineH1 and serotonin 5-HT2 receptor antagonist
Mechanism of action
Antagonises histamine H1 receptors and serotonin 5-HT2 receptors, with additional anticholinergic activity. This reduces allergic symptoms and can influence appetite and serotonergic signalling.
Indications / reported uses
  • Symptomatic relief of allergic rhinitis, urticaria and pruritus in authorised products
  • Treatment of selected serotonin-mediated conditions such as serotonin syndrome is off-label and specialist-directed; appetite stimulation is not a universal approved indication

Sources: US DailyMed — Cyproheptadine hydrochloride · NLM MeSH — Cyproheptadine · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Cyproheptadine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cyproheptadine Permitted Daily Exposure (PDE) report (the Cyproheptadine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cyproheptadine Occupational Exposure Limit (OEL) report (the Cyproheptadine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.